Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 7/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.61 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.61 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PRF1 | P14222 | 2/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.48 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133684 | 0.80 | APP (0.54) | APPESR1ESR2CYP2E1CYP3A4 | |
| SCHEMBL9538845 | 0.80 | APP (0.54) | APPCYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL1134019 | 0.80 | APP (0.54) | APPESR1ESR2CYP2E1CYP3A4 | |
| SCHEMBL7905308 | 0.80 | APP (0.68) | APPCYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL1133750 | 0.80 | APP (0.54) | APPCYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL1133819 | 0.80 | APP (0.54) | APPESR1CYP2E1CYP3A4CYP2A6 | |
| SCHEMBL2018651 | 0.79 | APP (0.51) | APPESR1ESR2CYP2E1CYP3A4 | |
| SCHEMBL2015912 | 0.79 | APP (0.54) | APPCYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL70783 | 0.79 | APP (0.67) | APPCYP2E1CYP3A4CYP2A6CYP2C9 | |
| SCHEMBL3630228 | 0.78 | APP (0.81) | APPCYP2E1CYP3A4CYP2A6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120081836-A | Response near infrared fluorescent probe targeting butyrylcholinesterase and beta amyloid, and preparation method and application thereof | 湖北大学 | 2025-06-03 | — | — | CN | claimed |
| CN-120081836-A | Response near infrared fluorescent probe targeting butyrylcholinesterase and beta amyloid, and preparation method and application thereof | 湖北大学 | 2025-06-03 | — | — | CN | disclosed |
| CN-115353495-B | Preparation method and application of furazolidone metabolite AOZ-derived hapten, complete antigen and serum antibody | 江西农业大学 | 2024-01-23 | — | — | CN | disclosed |
| CN-115353495-A | Preparation method and application of furazolidone metabolite AOZ-derived hapten, complete antigen and serum antibody | 江西农业大学 | 2022-11-18 | — | — | CN | disclosed |
| CN-112500437-B | Platinum epoxide complex and preparation method and application thereof | 河北医科大学 | 2022-08-02 | — | — | CN | disclosed |
| CN-112500437-A | Platinum epoxide complex and preparation method and application thereof | 河北医科大学 | 2021-03-16 | — | — | CN | disclosed |
| EP-2609089-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012025638-A1 | SELECTIVE 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | Universität des Saarlandes (DE) | 2012-03-01 | — | — | WO | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | APP 424/4885ESR1 4805/4885ESR2 4355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.